Abstract #0885

PET/MRI in Pancreatic and Periampullary Cancer: Correlating Diffusion-weighted Imaging, MR spectroscopy, and Glucose Metabolic Activity With Clinical Stage

Bang-Bin Chen¹, Yu-Wen Tien², Ming-Chu Chang³, Mei-Fang Cheng⁴, Yu-Ting Chang³, Chih-Horng Wu¹, Xin-Jia Chen¹, Ting-Chun Kuo², Shih-Hung Yang⁵, I-Lun Shih¹, Hong-Shiee Lai², and Tiffany Ting-Fang Shih¹

¹Medical Imaging and Radiology, National Taiwan University Medical School and Hospital, Taipei, Taiwan, ²Surgery, National Taiwan University Medical School and Hospital, Taipei, Taiwan, ³Internal Medicine, National Taiwan University Medical School and Hospital, Taipei, Taiwan, ⁴Nuclear Medicine, National Taiwan University Medical School and Hospital, Taipei, Taiwan, ⁵Oncology, National Taiwan University Medical School and Hospital, Taipei, Taiwan

We demonstrated that PET/MRI provides numerous useful imaging biomarkers for clinical staging and pathological grading in patients with pancreatic cancer or periampullary cancer. ADCmin was lower in tumors with N1 and an advanced TNM stage. Choline levels were higher in T4 and poorly differentiated tumors. Tumors with high glucose metabolic activity, as reflected by MTV and TLG, were at a more advanced T stage, exhibited lymph node and distant metastasis, and were at an advanced TNM stage. Moreover, compared with MTV or ADCmin alone, the MTV/ADCmin ratio demonstrated the highest predictive ability for determining the clinical TNM stage. Thus, integrated PET/MRI could provide complementary information on tumor characteristics, and these combined data could have stronger clinical or pathological implications than MRI or PET alone.

This abstract and the presentation materials are available to members only; a login is required.

Join Here